In other tumours, studies have shown that when SMARCA2/SMARCA4 is inactive, the cells become more sensitive to DNA damage, making chemotherapy and radiation therapy more effective. Developing inhibitors for these proteins may enhance the therapeutic effects, and in bladder cancer, multiple subunits are inactive, which may also lead to similar therapeutic effects. Here, SMARCA2 is linked to urinary bladder carcinoma.